Skip to main content

Brilinta Disease Interactions

There are 5 disease interactions with Brilinta (ticagrelor).

Major

Ticagrelor (applies to Brilinta) bleeding

Major Potential Hazard, High plausibility. Applicable conditions: Peptic Ulcer

Ticagrelor is contraindicated in patients with active pathological bleeding, such as peptic ulcer or intracranial hemorrhage.

References

  1. "Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals (2011):
Major

Ticagrelor (applies to Brilinta) liver dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Ticagrelor is metabolized by the liver. The use of ticagrelor should be avoided in patients with severe hepatic impairment. Care should be taken in patients with moderate hepatic impairment and it is recommended to consider the risks and benefits of treatment due to the probable increase in exposure to ticagrelor. No dosage adjustment is needed in patients with mild hepatic impairment.

References

  1. "Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals (2011):
Moderate

Ticagrelor (applies to Brilinta) bradyarrhythmias

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Sinus Node Dysfunction

Ticagrelor can cause ventricular pauses. Bradyarrhythmias including AV block have been reported in the postmarketing setting. It is recommended to use care if prescribing this agent to patients with a history of sick sinus syndrome, 2nd or 3rd degree AV block or bradycardia-related syncope not protected by a pacemaker as they may be at increased risk of developing bradyarrhythmias.

References

  1. "Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals (2011):
Moderate

Ticagrelor (applies to Brilinta) dyspnea

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment

Dyspnea has been reported with the use of ticagrelor. Care should be taken when prescribing this drug to patients that experienced dyspnea. If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to the drug, no specific treatment is required; continue treatment and monitoring without interruption, if possible. In the case of intolerable dyspnea requiring discontinuation, consider prescribing another antiplatelet agent.

References

  1. "Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals (2011):
Moderate

Ticagrelor (applies to Brilinta) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: hemodialysis

No dosage adjustment is needed in patients with renal impairment. Patients receiving dialysis have not been studied, close monitoring is recommended.

References

  1. "Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals (2011):

Brilinta drug interactions

There are 474 drug interactions with Brilinta (ticagrelor).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer